ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice
by Zacks Equity Research
Does ImmunoGen (IMGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
by Zacks Equity Research
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.
ImmunoGen (IMGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for ImmunoGen (IMGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
New Strong Buy Stocks for November 29th
by Zacks Equity Research
TM, PAY, WRB, MNDY and IMGN have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2023.
Wall Street Analysts Believe ImmunoGen (IMGN) Could Rally 52.99%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for ImmunoGen (IMGN) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
New Strong Buy Stocks for November 22nd
by Zacks Equity Research
RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.
Best Momentum Stocks to Buy for November 16th
by Zacks Equity Research
IMGN, MDV and VECO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 16:
New Strong Buy Stocks for November 16th
by Zacks Equity Research
IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.
ImmunoGen (IMGN) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
ImmunoGen (IMGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?
Best Momentum Stocks to Buy for November 8th
by Zacks Equity Research
APPF, IMGN and COIN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2023.
Zacks.com featured highlights include Confluent, Pinterest, ICON and ImmunoGen
by Zacks Equity Research
Confluent, Pinterest, ICON and ImmunoGen are part of the Zacks Screen of the Week article.
4 Stocks to Invest in for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.
Wall Street Analysts See a 40.58% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 40.6% upside potential for ImmunoGen (IMGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
by Zacks Equity Research
ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.
ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 400% and 6.02%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Catalent (CTLT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?
by Zacks Equity Research
ImmunoGen (IMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen
by Zacks Equity Research
Fresenius Medical Care, Vericel and ImmunoGen are part of the Zacks Investment Ideas article.
Top Medical Stocks to Buy Amid Recent Market Volatility
by Shaun Pruitt
Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.